Literature DB >> 15853992

Evaluation of predictive value of CLIP, Okuda, TNM and JIS staging systems for hepatocellular carcinoma patients undergoing surgery.

Yi-Hsiang Huang1, Chien-Hung Chen, Ting-Tsung Chang, Shinn-Cherng Chen, Shen-Yung Wang, Hsuan-Shu Lee, Pin-Wen Lin, Guan-Tarn Huang, Jin-Chuan Sheu, Hong-Ming Tsai, Pui-Ching Lee, Gar-Yang Chau, Wing-Yiu Lui, Shou-Dong Lee, Jaw-Ching Wu.   

Abstract

BACKGROUND: An accurate staging system is required to assess hepatocellular carcinoma (HCC) patients in order to benefit from hepatic resection before surgery. Cancer of the Liver Italian Program (CLIP) score was considered to be better than the Okuda staging system to predict survival. Japan Integrated Staging Score (JIS score) includes tumor, nodes, metastases (TNM) stage and Child-Pugh grade as a new staging system for HCC. The purpose of the present paper was to compare the CLIP, Okuda, TNM and JIS staging systems for HCC patients undergoing surgery.
METHODS: From 1991 to 1995, 599 patients undergoing hepatic resection for HCC from four medical centers in Taiwan were evaluated. All patients were classified by Okuda, CLIP, TNM and JIS systems. Factors associated survivals were analyzed.
RESULTS: There was no statistical difference in survival between CLIP 0 and 1 patients, or among CLIP 2-4 patients. The prognostic validation of the Okuda and CLIP scoring systems in discriminating survival in HCC patients undergoing surgery was not satisfied. The TNM system was successful in predicting survival for HCC patients undergoing surgery. The JIS score could also differentiate survivals for those patients except for JIS 3. By multivariate analysis, age > or =60 years old, serum albumin <3.5 g/dL, tumor size >5 cm and TNM stage were associated with survival.
CONCLUSION: Both the Okuda and CLIP systems are not superior to TNM staging for HCC patients who undergo surgical resection. Whether JIS score is feasible for those patients with advanced HCC needs further evaluation.

Entities:  

Mesh:

Year:  2005        PMID: 15853992     DOI: 10.1111/j.1440-1746.2005.03746.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  18 in total

1.  Vascular microinvasion from hepatocellular carcinoma: CT findings and pathologic correlation for the best therapeutic strategies.

Authors:  Alfonso Reginelli; Angelo Vanzulli; Cristiano Sgrazzutti; Luca Caschera; Nicola Serra; Antonio Raucci; Fabrizio Urraro; Salvatore Cappabianca
Journal:  Med Oncol       Date:  2017-04-12       Impact factor: 3.064

2.  Edmondson-Steiner grading increases the predictive efficiency of TNM staging for long-term survival of patients with hepatocellular carcinoma after curative resection.

Authors:  Li Zhou; Jing-An Rui; Da-Xiong Ye; Shao-Bin Wang; Shu-Guang Chen; Qiang Qu
Journal:  World J Surg       Date:  2008-08       Impact factor: 3.352

Review 3.  Staging systems of hepatocellular carcinoma: a review of literature.

Authors:  Marcello Maida; Emanuele Orlando; Calogero Cammà; Giuseppe Cabibbo
Journal:  World J Gastroenterol       Date:  2014-04-21       Impact factor: 5.742

Review 4.  Overview of Staging Systems for Hepatocellular Carcinoma and Implications for Interventional Radiology.

Authors:  Jan Hansmann; Charles E Ray
Journal:  Semin Intervent Radiol       Date:  2017-06-01       Impact factor: 1.513

5.  Early identification of poor responders to transarterial chemoembolization for hepatocellular carcinoma.

Authors:  Ya-Ju Tsai; Chia-Yang Hsu; Yi-Hsiang Huang; Chien-Wei Su; Han-Chieh Lin; Rheun-Chuan Lee; Jen-Huey Chiang; Teh-Ia Huo; Shou-Dong Lee
Journal:  Hepatol Int       Date:  2011-04-30       Impact factor: 6.047

6.  Tumor and liver determinants of prognosis in unresectable hepatocellular carcinoma: a large case cohort study.

Authors:  Brian I Carr; Petr Pancoska; Robert A Branch
Journal:  Hepatol Int       Date:  2009-12-24       Impact factor: 6.047

7.  Transarterial chemoembolization can prolong survival for patients with metastatic hepatocellular carcinoma: a propensity score matching analysis.

Authors:  I-Cheng Lee; Teh-Ia Huo; Yi-Hsiang Huang; Yee Chao; Chung-Pin Li; Pui-Ching Lee; Jen-Huey Chiang; Chien-Wei Su; Keng-Hsin Lan; Chih-Ming Yang; Jaw-Ching Wu; Han-Chieh Lin; Shou-Dong Lee
Journal:  Hepatol Int       Date:  2011-11-30       Impact factor: 6.047

8.  Health-related quality of life evaluated by tumor node metastasis staging system in patients with hepatocellular carcinoma.

Authors:  Cui-Xia Qiao; Xiao-Feng Zhai; Chang-Quan Ling; Qing-Bo Lang; Hui-Juan Dong; Qun Liu; Mou-Duo Li
Journal:  World J Gastroenterol       Date:  2012-06-07       Impact factor: 5.742

9.  Outcomes and prognostic factors of cirrhotic patients with hepatocellular carcinoma after radical major hepatectomy.

Authors:  Li Zhou; Jing-An Rui; Shao-Bin Wang; Shu-Guang Chen; Qiang Qu; Tian-Yi Chi; Xue Wei; Kai Han; Ning Zhang; Hai-Tao Zhao
Journal:  World J Surg       Date:  2007-09       Impact factor: 3.352

Review 10.  Interventional therapies for hepatocellular carcinoma.

Authors:  Jonathon M Willatt; Isaac R Francis; Paula M Novelli; Ranjith Vellody; Amit Pandya; V N Krishnamurthy
Journal:  Cancer Imaging       Date:  2012-04-05       Impact factor: 3.909

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.